| Element List | Explanation |
|---|---|
| Introduction | Saudi Chemical Company Holding announces, through its subsidiary Aja Pharmaceutical Industries Company, the signing of a non-exclusive agreement with Glaxo Saudi Arabia Limited (GSK) to provide medical marketing services for a wide range of its pharmaceutical products in the Kingdom of Saudi Arabia, through the field medical teams of Aja Pharmaceutical Industries Company. The agreement was signed on 15 June 2026. The services will be executed by the specialized teams of Aja Pharmaceutical Industries Company, in accordance with the terms and conditions agreed upon between the two parties. |
| Date of Announcement of the Award | 2026-06-15 Corresponding to 1447-12-29 |
| Contract Subject Matter | The company entered into a non-exclusive agreement with Glaxo Saudi Arabia Limited (GSK) to provide medical marketing services for a wide range of pharmaceutical products belonging to Glaxo Saudi Arabia Limited (GSK) within the Kingdom of Saudi Arabia. |
| The Entity with Which the Contract was Signed | Glaxo Saudi Arabia Limited (GSK). |
| Date of Signing the Contract | 2026-06-15 Corresponding to 1447-12-29 |
| Contract Value | The financial consideration for the agreement is linked to a percentage of the sales of Glaxo Saudi Arabia Limited (GSK) products in the Saudi market, in addition to performance indicators and the achievement of operational targets throughout the contract term. The annual value of the contract is expected to be less than 5% of the Group’s revenues. |
| Contract Details | This agreement supports the Company’s strategy to expand its contract sales and medical services capabilities in the Saudi market. The agreement was concluded on an arm’s length basis and in the ordinary course of business. |
| Contract Duration | Three years, with an opportunity to renew. |
| Financial Impact and the Relevant Period | The agreement is expected to have a positive impact on the Company’s revenues and operational performance throughout the contract period, with the financial impact expected to commence from the third quarter of 2026. |
| Related Parties | No related parties are involved. |
| Additional Information | N/A |
